ISSN: 2332-0877

感染症と治療ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Synergy Testing between Sulbactam and Meropenem/ Colistin in MDR Acinetobacter baumannii-calcoaceticus Complex Isolated from Ventilator Associated Pneumonia

Shalini Anandan, Lydia Jennifer, Shalini Anandan, Agila Kumari Pragasam, Baby Abirami Shankar, Balaji Veeraraghavan, John Victor Peter and Shoma V Rao

Background: A. baumannii-calcoaceticus (Abc) complex has surfaced as a major nosocomial pathogen causing blood stream infection and ventilators associated pneumonia (VAP). Carbapenems have come to be the cornerstone of treatment for Abc complex. However, there has been an increased incidence of infections with carbapenem resistant strains. To validate the clinical practice of combination antibiotic therapy, in-vitro combinations of antibiotics have been examined using checkerboard methods, E-tests, and the reference, time-kill assay.

Method: A prospective pilot study was conducted for the duration of one year. Twenty five isolates of carbapenem resistant Abc complex cultured from endotracheal aspirates of patients admitted in medical and surgical intensive care units diagnosed with ventilator associated pneumonia were collected. Isolates were tested for MIC (Minimum inhibitory concentration) by micro-broth dilution method for meropenem, sulbactam and colistin. Synergism between sulbactam plus meropenem and sulbactam plus colistin was tested by micro-broth checkerboard assay and the reference, time kill assay.

Result: Minimum inhibitory concentration ranges (μg/ml) for sulbactam, meropenem, and colistin were 16-512, 16-256, and 0.5-64, respectively. MIC50 for sulbactam, meropenem, and colistin was 128, 128 and 1, correspondingly, and MIC90 for sulbactam, meropenem, and colistin was 256, 256 and 2, respectively. In the checkerboard assay and time-kill assay, a higher percentage of synergy was noted for the combination of sulbactam plus meropenem.

Conclusion: Against multi-drug resistant (MDR) isolates of Abc complex, commendable synergy was seen with time kill assay for sulbactam plus meropenem combination. Therefore, in-vitro combinations of antimicrobial agents are most effective than the single agent against multidrug resistant organism.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません。